Immunogenicity of Biosimilar Therapeutics in Drug Development (Q167968): Difference between revisions

Revision as of 14:05, 30 August 2024

Investigating the safety and effectiveness of biosimilar drugs, including testing methods and potential side effects.

Language	Label	Description	Also known as
English	Immunogenicity of Biosimilar Therapeutics in Drug Development	Investigating the safety and effectiveness of biosimilar drugs, including testing methods and potential side effects.	Biosimilars Immunogenicity Bioanalytical Methods Therapeutic Proteins Dried Blood Spots Erythropoietin Antibodies Monoclonal Antibodies Regulatory Guidelines Biopharmaceuticals Clinical Outcomes

0 references

0 references

Revision as of 14:10, 24 May 2024 Sky (talk \| contribs) (‎Created a new Item: Added new OpenAlex topic claimed by USGS staff from API)		Revision as of 14:05, 30 August 2024 Sky (talk \| contribs) (‎Changed label, description and/or aliases in en, and other parts: modified description with assistance from Llama 3.1) Newer edit →
description / en		description / en
	~~This cluster of papers focuses on~~ the ~~immunogenicity~~ of biosimilar ~~therapeutics~~, including ~~the validation of bioanalytical~~ methods ~~for assessing immunogenicity, the impact of manufacturing changes on immunogenicity, and the clinical outcomes~~ and ~~safe~~		Investigating the safety and effectiveness of biosimilar drugs, including testing methods and potential side effects.